Summary

The hypopigmentation disorder treatment market is expected to grow from US$ 4.4 billion in 2023 to US$ 6.7 billion by 2031; it is anticipated to record a CAGR of 5.41% from 2023 to 2031.

Hypopigmentation disorder treatment includes skin conditions where the skin lacks normal pigmentation, which results in lighter or white patches. Several therapeutics of hypopigmentation aim to restore or balance skin color. topical corticosteroids, Phototherapy, and depigmentation are common approaches. Emerging technologies, such as laser therapy and cell-based treatments, are shown to promise in repigmenting affected areas of patients. Treatment plans for hypopigmentary disorders are tailored based on specific disorders such as PIH, vitiligo or albinism.

Increasing prevalence of hypopigmentary disorders and advancements in dermatological research drive the growth of the Hypopigmentation Disorder Treatment market.

The rising prevalence of hypopigmentation disorders, such as vitiligo and albinism. For instance, according to the data published in Annals of Palliative Medicine in July 2021, prevalence of vitiligo was reported to range from 0.1% to 8% globally, and vitiligo has been linked to some autoimmune and non-autoimmune diseases and increased awareness and early diagnosis contribute to the increasing patient pool seeking therapeutic interventions. Additionally, a surge in cosmetic consciousness people and the aesthetically pleasing skin among those people further propel the market, with individuals seeking treatments to address hypopigmentation- disorders.

Secondly, advancements in dermatological research and technology resulted in the development of innovative treatments, including phototherapy, topical therapies, and surgical procedures, enhancing the efficacy and scope of available solutions. Moreover, favorable reimbursement policies and expanding treatment strategy related to hypopigmentation disorder treatment market size contribute to market growth. Collaboration and partnerships among pharmaceutical companies and research institutions accelerate the development of novel therapies. Furthermore, the global aging population and the associated increase in skin-related disorders amplify the demand for hypopigmentation disorder treatments. Overall, the hypopigmentation disorder treatment market is dynamic and responsive to evolving patient needs, technological innovations, and collaborative efforts within the healthcare industry.

The hypopigmentation disorder treatment market analysis has been carried out by considering the following segments: based on treatment, disease indication, and end user. By treatment, the market is classified into basic topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others. Based on disease indication, the market is segmented into pityriasis alba, vitiligo, albinism, and post-inflammatory hypopigmentation. In terms of end user, the market is classified into aesthetics clinics, dermatology centers and hospitals. The geographic scope of the hypopigmentation disorder treatment market report includes North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

In terms of revenue North America dominated the hypopigmentation disorder treatment market share owing to a higher prevalence of patients suffering from hypo pigmentary disorders in the US. Furthermore, factors like demand for hypopigmentation therapeutics, increasing prevalence of pigmentation disorder such as vitiligo and rising awareness related to hypopigmentation disorders is further driving the market growth. The US hypopigmentation disorder treatment market is growing owing to various factors such as key product introductions, a high concentration of manufacturers or market players, and alliances and acquisitions among prominent competitors. Furthermore, the strategic presence of key players positions US is a key country for the Hypopigmentation Disorder Treatment Market growth. For instance, according to the Journal of American Academy of Dermatology in December 2020, Vitiligo global prevalence is ∼0.5%-2%, with reported rates varying geographically .

ページTOPに戻る

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Hypopigmentation Disorder Treatment Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Hypopigmentation Disorder Treatment Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Hypopigmentation Disorder Treatment Market - Global Market Analysis
6.1 Hypopigmentation Disorder Treatment - Global Market Overview
6.2 Hypopigmentation Disorder Treatment - Global Market and Forecast to 2031
7. Hypopigmentation Disorder Treatment Market – Revenue Analysis (USD Million) – By Treatment, 2021-2031
7.1 Overview
7.2 Topical Drugs
7.3 Laser Therapy
7.4 Chemical Peels
7.5 Microdermabrasion
7.6 Phototherapy
7.7 Skin Grafting
7.8 Pigment cell transplantation
7.9 Others
8. Hypopigmentation Disorder Treatment Market – Revenue Analysis (USD Million) – By Disease Indication, 2021-2031
8.1 Overview
8.2 Vitiligo
8.3 Albinism
8.4 Hypopigmented/depigmented scars
8.5 Melasma
8.6 Post-Inflammatory Hypopigmentation (PIH)
8.7 Others
9. Hypopigmentation Disorder Treatment Market – Revenue Analysis (USD Million) – By End User, 2021-2031
9.1 Overview
9.2 Hospitals
9.3 Aesthetic Clinics
9.4 Dermatology Centers
9.5 Others
10. Hypopigmentation Disorder Treatment Market - Revenue Analysis (USD Million), 2021-2031 – Geographical Analysis
10.1 North America
10.1.1 North America Hypopigmentation Disorder Treatment Market Overview
10.1.2 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts to 2031
10.1.3 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Treatment
10.1.4 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Disease Indication
10.1.5 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By End User
10.1.6 North America Hypopigmentation Disorder Treatment Market Revenue and Forecasts and Analysis - By Countries
10.1.6.1 United States Hypopigmentation Disorder Treatment Market
10.1.6.1.1 United States Hypopigmentation Disorder Treatment Market, by Treatment
10.1.6.1.2 United States Hypopigmentation Disorder Treatment Market, by Disease Indication
10.1.6.1.3 United States Hypopigmentation Disorder Treatment Market, by End User
10.1.6.2 Canada Hypopigmentation Disorder Treatment Market
10.1.6.2.1 Canada Hypopigmentation Disorder Treatment Market, by Treatment
10.1.6.2.2 Canada Hypopigmentation Disorder Treatment Market, by Disease Indication
10.1.6.2.3 Canada Hypopigmentation Disorder Treatment Market, by End User
10.1.6.3 Mexico Hypopigmentation Disorder Treatment Market
10.1.6.3.1 Mexico Hypopigmentation Disorder Treatment Market, by Treatment
10.1.6.3.2 Mexico Hypopigmentation Disorder Treatment Market, by Disease Indication
10.1.6.3.3 Mexico Hypopigmentation Disorder Treatment Market, by End User
Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Rest of Europe
10.3 Asia-Pacific
10.3.1 Australia
10.3.2 China
10.3.3 India
10.3.4 Japan
10.3.5 South Korea
10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
10.4.1 South Africa
10.4.2 Saudi Arabia
10.4.3 U.A.E
10.4.4 Rest of Middle East and Africa
10.5 South and Central America
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Rest of South and Central America
11. Industry Landscape
11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments
12. Competitive Landscape
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration
13. Hypopigmentation Disorder Treatment Market - Key Company Profiles
13.1 Allergan
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
Note - Similar information would be provided for below list of companies

13.2 SkinCeuticals
13.3 Pierre Fabre
13.4 Episciences, Inc
13.5 RXi Pharmaceuticals Corporation
13.6 Obagi Cosmeceuticals LLC
13.7 Incyte
13.8 L’oréal Paris
13.9 CLINUVEL PHARMACEUTICALS LTD
13.10 STRATA Skin Sciences
13.11 TeVido BioDevices, Inc.
13.12 Courage + Khazaka electronic GmbH
13.13 AVITA Medical
13.14 Galderma S.A.
13.15 Vital Esthetique
14. Appendix
14.1 Glossary
14.2 About The Insight Partners
14.3 Market Intelligence Cloud